Syneos Health (NASDAQ:SYNH) Stock Rating Lowered by Deutsche Bank Aktiengesellschaft

Syneos Health (NASDAQ:SYNH – Get Rating) was downgraded by analysts at Deutsche Bank Aktiengesellschaft from a “buy” rating to a “hold” rating in a note issued to investors on Thursday, The Fly reports.

SYNH has been the subject of a number of other research reports. Barclays raised shares of Syneos Health from an “underweight” rating to an “equal weight” rating in a research note on Wednesday. Mizuho reaffirmed a “neutral” rating and set a $38.00 target price on shares of Syneos Health in a research note on Friday, February 17th. JPMorgan Chase & Co. raised shares of Syneos Health from an “underweight” rating to a “neutral” rating in a research note on Wednesday. Robert W. Baird raised their target price on shares of Syneos Health from $42.00 to $51.00 and gave the company an “outperform” rating in a research note on Friday, February 17th. Finally, StockNews.com began coverage on shares of Syneos Health in a research report on Thursday, March 16th. They set a “hold” rating for the company. Ten research analysts have rated the stock with a hold rating, According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $50.78.

Syneos Health Price Performance

SYNH stock opened at $41.66 on Thursday. Syneos Health has a 1 year low of $22.89 and a 1 year high of $79.77. The company has a market cap of $4.30 billion, a P/E ratio of 16.21 and a beta of 1.62. The firm has a 50-day moving average of $37.43 and a 200 day moving average of $36.96. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.13 and a quick ratio of 1.13.

Syneos Health (NASDAQ:SYNH – Get Rating) last announced its earnings results on Thursday, February 16th. The company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.07 by $0.08. Syneos Health had a net margin of 4.94% and a return on equity of 13.19%. The business had revenue of $1.36 billion during the quarter, compared to the consensus estimate of $1.29 billion. On average, sell-side analysts forecast that Syneos Health will post 2.85 EPS for the current year.

Institutional Investors Weigh In On Syneos Health

A number of large investors have recently added to or reduced their stakes in SYNH. Cetera Advisor Networks LLC grew its position in Syneos Health by 11.1% in the 1st quarter. Cetera Advisor Networks LLC now owns 3,725 shares of the company’s stock worth $302,000 after purchasing an additional 372 shares during the period. Bank of Montreal Can grew its position in Syneos Health by 55.6% in the 1st quarter. Bank of Montreal Can now owns 69,809 shares of the company’s stock worth $5,697,000 after purchasing an additional 24,933 shares during the period. Great West Life Assurance Co. Can boosted its stake in shares of Syneos Health by 8.0% during the 1st quarter. Great West Life Assurance Co. Can now owns 56,664 shares of the company’s stock worth $4,716,000 after acquiring an additional 4,203 shares during the last quarter. Cibc World Market Inc. boosted its stake in shares of Syneos Health by 214.3% during the 1st quarter. Cibc World Market Inc. now owns 22,133 shares of the company’s stock worth $1,792,000 after acquiring an additional 15,091 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Syneos Health by 0.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,042,500 shares of the company’s stock worth $84,394,000 after acquiring an additional 5,999 shares during the last quarter. Institutional investors own 93.51% of the company’s stock.

Syneos Health Company Profile

(Get Rating)

Syneos Health, Inc engages in the provision of biopharmaceutical solutions. It operates through the Clinical Solutions and Commercial Solutions segments. The Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics that span Phase I to IV of clinical development.